CELLAVISION AB (publ) - Year-End Bulletin 2008

2009-02-16 - English

January - December
  •    Net sales increased by 35 % to SEK 100.4 million (74.6).
  •    The operating result increased to SEK 13.4 million (3.1).  
  •    Profit before income tax increased to SEK 13.1 million (2.6).
  •    The net result per share amounted to SEK 1.05 (0.11).
  •    Cash and cash equivalents amounted to SEK 19.6 million (16.3) by the end of the year. 
  •    Continued strong sales on the European market and an increase in North America.
  •    Establishment of own sales organization in the USA and subsidiary in Japan.
  •    Launch of application for body fluids in Europe and North America, with good initial sales results.
  •  
    October - December
  •    Net sales for the fourth quarter increased by 97 % to SEK 38.3 million (19.4).
  •    The operating result amounted to SEK 7.1 million (3.0).
  •    Result per share amounted to SEK 0.80 (0.12).
  •  
    Important events after the reporting period
  •    CellaVision was placed on NASDAQ OMX First North Premier on the 16th of February.
  •  
     
     
     
    CEO's comment
    "It feels fantastic to report our highest sales and best result so-far," says Yvonne Mårtensson, CEO of CellaVision. "Our international expansion has proceeded according to plan and we have succeeded in investing alongside increasing sales. We are now operative in Japan and have established our own sales channel in the US. As a result of Sysmex America's and our own sales activities the North American sales proportion reached 45%.  Europe is seeing a continued positive sales growth and accounts for 54% of CellaVision's sales."
     
    "2009 will be a year of challenges. Although medical technology companies are generally regarded relatively stable, it would be unreasonable to rule out the possibility of our industry being negatively affected by the world economy. However, we believe that our presence in a large number of countries combined with the efficiency of our products is a winning concept also during rough financial times. We are well equipped for future challenges."
     
     
    For more information please contact:
    Yvonne Mårtensson, CEO. Phone: 0708 33 77 82, e-mail: yvonne.martensson@cellavision.se  
    Johan Wennerholm, CFO. Phone: 0708 33 81 68, e-mail: johan.wennerholm@cellavision.se
     
     
    Download the report by pressing the link below.

    PDF version: CellaVision AB (publ) - Year-End Bulletin 2008

    Subscribe to updates

    It's possible to subscribe to CellaVision's press releases, financial information by e-mail and SMS.

    Click here to register


    Information request

    Are you looking for some particular information about our company or our business?

    Click here to get in touch


    Analyst

    ABG Sundal Collier AB
    Sten Gustafsson
    +46 8 566 286 93

    Pareto Securities AB
    Christian Lee
    +46 8 402 52 67

     

    Access our Student Resources

    To access this resource, please provide the following information about yourself.